- ￥10600 - 17500
- TargetMol
- 美国
- T62488
- 2025年07月11日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
零下80~20°C
- 保质期：
Powder: -20°C for 3 years In solvent: -80°C for 2 years
- 英文名：
P2X7 receptor antagonist-1
- 库存：
10
- 供应商：
TargetMol
- 规格：
100 mg/50 mg/25 mg
| 规格： | 100 mg | 产品价格： | ￥17500.0 |
|---|---|---|---|
| 规格： | 50 mg | 产品价格： | ￥13800.0 |
| 规格： | 25 mg | 产品价格： | ￥10600.0 |
Product Introduction
Bioactivity
英文名:P2X7 receptor antagonist-1
描述:P2X7 receptor antagonist-1 is a purinergic P2X7 receptor antagonist with anti-neuroinflammatory effects.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Chemokine Receptor Antagonist Development
This chapter describes assays that focus on the characterization of compounds identified in high-�throughput screening campaigns, and the subsequent medicinal chemistry programs. They cover methods to determine potency
Developing a Photoreactive Antagonist
approach for developing small molecules that, upon irradiation with light, may be used to rapidly inactivate targeted proteins expressed on the surfaces of cells. Highlighted is ANQX, a photoreactive AMPA receptor antagonist developed to irreversibly
Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist
than clopidogrel without an unacceptable increase in hemorrhagic or other side effects. Prasugrel (CS-747; LY-640315), a novel third-generation oral thienopyridine, is a specific, irreversible antagonist of the platelet ADP P2Y12 receptor. Pre-clinical and early
技术资料暂无技术资料 索取技术资料
